Medical therapies for meningiomas

Area of Science:

• Neuro-oncology
• Medical Therapies for Brain Tumors
• Molecular Pathogenesis of Meningiomas

Background:

• Meningiomas are the most frequent primary brain tumors in adults.
• While surgery and radiotherapy are effective for many, a significant portion of patients present with inoperable tumors or experience recurrence.
• These patients require effective medical therapies, but current options have yielded disappointing results.

Purpose of the Study:

• To review the current landscape of medical therapies for meningiomas.
• To identify promising therapeutic avenues, particularly targeted molecular therapies.
• To highlight the need for improved understanding and clinical trial strategies.

Main Methods:

• Review of existing studies on medical therapies for meningiomas.
• Analysis of the efficacy of chemotherapies, hormonal therapies, and targeted molecular agents.
• Discussion of challenges in preclinical modeling and clinical trial design.

Main Results:

• Conventional chemotherapies and hormonal therapies have demonstrated limited efficacy.
• Somatostatin analogues show potential therapeutic value.
• Targeted molecular therapies, particularly those inhibiting vascular endothelial growth factor receptors, show some promise, while others targeting platelet-derived and epidermal growth factor receptors have shown little efficacy.

Conclusions:

• Advances in meningioma medical therapy are hindered by disappointing results from current treatments.
• Targeted molecular therapies, especially anti-angiogenic agents, represent a promising area for future development.
• Further progress requires a deeper understanding of meningioma molecular biology, better preclinical models, and efficient clinical trial designs for this patient population.